A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis

Summary

This study is a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of ensifentrine inhalation suspension (3 mg) delivered twice daily via standard jet nebulizer over at least 24 weeks, compared to placebo, in subjects with non-cystic fibrosis bronchiectasis (NCFBE).

Timeline

Start

2024-09-11

Primary completion

2027-09-24

Completion

2027-09-24

Drugs

Indications